

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/682,712	10/09/2003	Ye Fang	SP03-139	9629	
22928	7590 07/07/2005		EXAM	EXAMINER	
CORNING INCORPORATED			JUNG,	JUNG, UNSU	
SP-TI-3-1					
CORNING, NY 14831			ART UNIT	PAPER NUMBER	
			1641		
			DATE MAILED: 07/07/2004	DATE MAILED: 07/07/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
Office Action Summary		10/682,712	FANG, YE		
		Examiner	Art Unit		
		Unsu Jung	1641		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SH THE - Exte after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REF MAILING DATE OF THIS COMMUNICATION nsions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. e period for reply specified above is less than thirty (30) days, a roperiod for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by state reply received by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may a reply be eply within the statutory minimum of thirty (30) od will apply and will expire SIX (6) MONTHS froute, cause the application to become ABANDOI	timely filed  ays will be considered timely.  om the mailing date of this communication.  NED (35 U.S.C. § 133).		
Status					
1)⊠	Responsive to communication(s) filed on 09	October 2003.			
		nis action is non-final.			
3)					
Disposit	ion of Claims				
5) 6) 7)	Claim(s) 1-22 is/are pending in the application 4a) Of the above claim(s) is/are withdown Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-22 are subject to restriction and/or	rawn from consideration.			
Applicat	ion Papers				
10)	The specification is objected to by the Examinate The drawing(s) filed on is/are: a) and a specificant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the	ccepted or b) objected to by the one drawing(s) be held in abeyance. Section is required if the drawing(s) is contact.	ee 37 CFR 1.85(a). Objected to. See 37 CFR 1.121(d).		
Priority (	under 35 U.S.C. § 119				
a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of:  1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure See the attached detailed Office action for a life	ents have been received. ents have been received in Applicationity documents have been received in Received in Received in Rule 17.2(a)).	ation No ved in this National Stage		
Attachmen		<b></b>			
2) Notice 3) Information	te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 ter No(s)/Mail Date	4) Interview Summa Paper No(s)/Mail  5) Notice of Informa 6) Other:			

Application/Control Number: 10/682,712

Art Unit: 1641

## **DETAILED ACTION**

Page 2

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - Claims 1-14, drawn to a method of using a biological membrane microarray for target evaluation, classified in class 435, subclass 7.72, for example.
  - II. Claim 15, drawn to a method for determining tissue distribution of a particular drug target, classified in class 435, subclass 7.2, for example.
  - III. Claim 16, drawn to a method for determining abnormal expression level of a particular drug target in a disease tissue or an abnormal cell, classified in class 436, subclass 519, for example.
  - IV. Claim 17, drawn to a method for determining protein-protein interaction, classified in class 436, subclass 528, for example.
  - V. Claim 18, drawn to a method for determining or profiling the relative level of membrane-interacting protein expression within a cell, classified in class 436, subclass 518, for example.
  - VI. Claim 19, drawn to a method for determining lipid receptor-protein interaction, classified in class 435, subclass 7.1, for example.
  - VII. Claim 20, drawn to a method for determining or profiling the level of membrane-interacting protein expression within a cell, classified in class 422, subclass 523, for example.